Cargando…
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
INTRODUCTION: The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellu...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374953/ https://www.ncbi.nlm.nih.gov/pubmed/18182100 http://dx.doi.org/10.1186/bcr1843 |
_version_ | 1782154544738729984 |
---|---|
author | Sassen, Andrea Rochon, Justine Wild, Peter Hartmann, Arndt Hofstaedter, Ferdinand Schwarz, Stephan Brockhoff, Gero |
author_facet | Sassen, Andrea Rochon, Justine Wild, Peter Hartmann, Arndt Hofstaedter, Ferdinand Schwarz, Stephan Brockhoff, Gero |
author_sort | Sassen, Andrea |
collection | PubMed |
description | INTRODUCTION: The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and cross-activation. The most famous family member is HER2, which is a target in Herceptin™ therapy in metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of gene amplification and resulting protein overexpression. The HER2-related HER receptors have been shown to interact directly with HER2 receptors and thereby mutually affect their activity and subsequent malignant growth potential. However, the clinical outcome with regard to total HER receptor state remains largely unknown. METHODS: We investigated HER1–HER4, at both the DNA and the protein level, using fluorescence in situ hybridisation (FISH) probes targeted to all four receptor loci and also immunohistochemistry in tissue microarrays derived from 278 breast cancer patients. RESULTS: We retrospectively found HER3 gene amplification with a univariate negative impact on disease-free survival (hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p = 0.031), whereas HER4 amplification showed a positive trend in overall and disease-free survival. Protein expression revealed no additional information. CONCLUSION: Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information. The continuation of explorative and prospective studies on all HER receptors will be required for an evaluation of their potential use for specific therapeutic targeting with respect to individualised therapy. |
format | Text |
id | pubmed-2374953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-23749532008-05-10 Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients Sassen, Andrea Rochon, Justine Wild, Peter Hartmann, Arndt Hofstaedter, Ferdinand Schwarz, Stephan Brockhoff, Gero Breast Cancer Res Research Article INTRODUCTION: The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and cross-activation. The most famous family member is HER2, which is a target in Herceptin™ therapy in metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of gene amplification and resulting protein overexpression. The HER2-related HER receptors have been shown to interact directly with HER2 receptors and thereby mutually affect their activity and subsequent malignant growth potential. However, the clinical outcome with regard to total HER receptor state remains largely unknown. METHODS: We investigated HER1–HER4, at both the DNA and the protein level, using fluorescence in situ hybridisation (FISH) probes targeted to all four receptor loci and also immunohistochemistry in tissue microarrays derived from 278 breast cancer patients. RESULTS: We retrospectively found HER3 gene amplification with a univariate negative impact on disease-free survival (hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p = 0.031), whereas HER4 amplification showed a positive trend in overall and disease-free survival. Protein expression revealed no additional information. CONCLUSION: Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information. The continuation of explorative and prospective studies on all HER receptors will be required for an evaluation of their potential use for specific therapeutic targeting with respect to individualised therapy. BioMed Central 2008 2008-01-08 /pmc/articles/PMC2374953/ /pubmed/18182100 http://dx.doi.org/10.1186/bcr1843 Text en Copyright © 2008 Sassen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sassen, Andrea Rochon, Justine Wild, Peter Hartmann, Arndt Hofstaedter, Ferdinand Schwarz, Stephan Brockhoff, Gero Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients |
title | Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients |
title_full | Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients |
title_fullStr | Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients |
title_full_unstemmed | Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients |
title_short | Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients |
title_sort | cytogenetic analysis of her1/egfr, her2, her3 and her4 in 278 breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374953/ https://www.ncbi.nlm.nih.gov/pubmed/18182100 http://dx.doi.org/10.1186/bcr1843 |
work_keys_str_mv | AT sassenandrea cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients AT rochonjustine cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients AT wildpeter cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients AT hartmannarndt cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients AT hofstaedterferdinand cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients AT schwarzstephan cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients AT brockhoffgero cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients |